Table 3.

Univariate and multivariate analyses for recurrence-free survival (RFS).

			RFS
			Univariate Analysis			Multivariate Analysis
Variables		N. Pts at risck	HR	95% CI	* p	HR	95% CI	* p
Age	<60 (Ref)	34
	≥60	157	0.84	0.49–1.44	0.54
Sex
	F (Ref)	54
	M	137	1.03	0.65–1.65	0.88
Smoking
	Never (Ref)	16
	Current	76	2.09	0.82–5.30	0.12
	Former	99	1.58	0.62–4.00	0.33
Histology
	Squamous (Ref)	69
	Adenocarcinoma	120	1.62	1.02–2.58	0.03	2.16	1.30–3.60	0.003
	Adenosquamous	2	1.39	0.18–10.25	0.32	1.36	0.17–10.46	0.76
p-Stage
	I (Ref)	101
	II	56	1.71	1.05–2.79	0.03	2.13	1.26–3.62	0.005
	III	34	2.01	1.17–3.41	0.01	2.13	1.20–3.80	0.01
PD-1
	Low < 4fc (Ref)	151
	High ≥ 4fc	40	1.17	0.70–21.96	0.52
PD-L1
	Low < 4fc (Ref)	77
	High ≥ 4fc	114	1.22	0.79–1.90	0.35
PD-L2
	Low < 4fc (Ref)	103
	High ≥ 4fc	88	1.41	0.92–2.15	0.11
IDO-1
	Low < 4fc (Ref)	110
	High ≥ 4fc	81	1.26	0.832–1.93	0.27
IDO-2
	Low < 4fc (Ref)	130
	High ≥ 4fc	61	1.33	0.85–2.08	0.20
INFγ
	Low < 4fc (Ref)	157
	High ≥ 4fc	34	1.55	0.93–2.59	0.08
PDL1/PDL2/INFγ
	Low < 4fc (Ref)	161
	High ≥ 4fc	30	1.90	1.13–3.21	0.01	1.98	1.06–3.71	0.03

Abbreviations: RFS, Recurrence-free Survival; HR, Hazard Ratio; CI, Confidence Interval; PD-1, programmed cell death 1; PD-L1, programmed cell death 1 ligand 1; PD-L2, programmed cell death 1 ligand 2; IDO-1, indoleamine 2,3-dioxygenase 1; IDO-2, indoleamine 2,3-dioxygenase 2; IFNγ, Interferon-γ; * p value ≤ 0.05 in bold.